Can Shield Bring More People into Colorectal Cancer Screening?

When assessing Shield, a blood test for colorectal cancer, as a business, the first question is how many people it can reach who have not previously participated in screening. Someone attracted by the prospect of a simple blood draw needs to take the test and, if the result is positive, proceed to a colonoscopy. If more people complete that pathway, the test could create value that its standalone performance cannot fully capture.

In the ECLIPSE study that supported its approval, sensitivity was 83.1% for colorectal cancer overall, 54.5% for Stage I cancer and 13.2% for advanced precancerous lesions. The results for this first-generation test show a particular weakness in detecting precancerous lesions. There is a gap between the hope of broadly detecting early lesions and the test's actual performance. Original NEJM study ↗ · FDA review documents ↗

A positive Shield result does not, on its own, determine treatment. A colonoscopy is needed to establish whether a lesion is present, with biopsy and pathological examination when necessary. Fecal occult blood tests and the stool DNA test Cologuard share this pathway. In addition to examining lesions, colonoscopy can allow polyps to be removed when appropriate. Unlike a test used to select a particular drug, this business connects screening to diagnosis and, in some cases, lesion removal. FDA product information ↗ · NCI explanation of colorectal cancer screening ↗

In Japan, this raises an obvious question: why not have a colonoscopy in the first place? When it is covered by health insurance, the patient's out-of-pocket cost is relatively modest. According to the National Cancer Center Hospital's guidance, the estimated cost for a patient with a 30% copayment is ¥5,000–7,000 for an examination alone, or ¥10,000–15,000 if a biopsy is performed. These figures, however, are estimates for care that qualifies for insurance coverage. Elective screening requested by someone without symptoms is treated differently. Bowel preparation, finding time, making an appointment and reluctance to undergo the examination remain barriers beyond cost. National Cancer Center Hospital guidance ↗ · National Hospital Organization guidance on elective screening ↗

In Japan, then, the competition is not just colonoscopy but also the fecal occult blood testing already in widespread use. How much would a blood test increase screening participation? Who would pay the additional cost of achieving that increase? These are central questions for assessing the business. Japan's 2024 guidelines recommend fecal occult blood testing for organized screening of people without symptoms. The value of colonoscopy as a follow-up diagnostic examination and the case for a screening policy that offers colonoscopy to everyone from the outset need to be evaluated under different conditions. National Cancer Center screening guidelines ↗

Sales are already growing in the United States. According to the company, approximately 66,000 Shield tests were performed in April–June 2026, up from approximately 16,000 in the same period a year earlier. Screening segment revenue rose from $14.8 million to $52.9 million over the same comparison period. These figures demonstrate growing demand. They do not, however, establish the long-term benefits of screening or Shield's standalone profitability. Guardant Health Q2 2026 results ↗

Access to patient data and established clinical pathways could also help with further improvements. Linking blood measurements to colonoscopy, pathology and subsequent outcomes would make it possible to investigate which lesions the test misses and what additional information might help. In my view, obtaining data that can be followed through to diagnosis matters more for both technology development and business assessment than simply increasing sales volumes.

Alongside test volumes, I would like to track the proportion of people being screened for the first time, colonoscopy completion after a positive result, the amounts actually paid for tests, testing costs and lesion-specific sensitivity in improved versions. Is growth coming mainly from people switching from existing screening methods, or from people who previously did not participate in screening? That distinction will make a substantial difference to how we assess Shield's growth.